Terumo Corporation Acquires OrganOx in $1.5 Billion Deal
Terumo Corporation, a Japanese health care equipment and supply manufacturer, has acquired OrganOx, an Oxford-based medtech company, for $1.5 billion. The acquisition is expected to strengthen Terumo’s position in the medical technology sector, particularly in the area of organ transplantation.
Acquisition Details
- Date: Not specified
- Value: $1.5 billion
- Parties involved: Terumo Corporation and OrganOx
Reasons for the Acquisition
The acquisition is seen as a strategic move by Terumo to expand its product offerings and increase its presence in the global market. This move is expected to have a positive impact on Terumo’s financial performance.
Market Impact
The global drug-eluting stent market is expected to experience growth, driven by increasing demand for minimally invasive cardiac procedures and next-generation designs that reduce the risk of restenosis.
Key Statistics
- The global drug-eluting stent market is expected to experience growth
- Increasing demand for minimally invasive cardiac procedures is driving market growth
- Next-generation designs that reduce the risk of restenosis are expected to contribute to market growth
